Radiogenomics: bridging imaging and genomics

1.

Coroller TP, Bi WL, Huynh E, Abedalthagafi M, Aizer AA, Greenwald NF, Parmar C, Narayan V, Wu WW, de Moura SMJPo (2017) Radiographic prediction of meningioma grade by semantic and radiomic features. 12 (11):e0187908

2.

Yip SS, Liu Y, Parmar C, Li Q, Liu S, Qu F, Ye Z, Gillies RJ, Aerts HJ (2017) Associations between radiologist-defined semantic and automatically computed radiomic features in non-small cell lung cancer. Scientific reports 7 (1):3519CrossRefPubMedPubMedCentral

3.

Gillies RJ, Kinahan PE, Hricak H (2016) Radiomics: Images Are More than Pictures, They Are Data. Radiology 278 (2):563-577. https://doi.org/10.1148/radiol.2015151169 CrossRefPubMed

4.

Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, Bussink J, Monshouwer R, Haibe-Kains B, Rietveld D, Hoebers F, Rietbergen MM, Leemans CR, Dekker A, Quackenbush J, Gillies RJ, Lambin P (2014) Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nature communications 5:4006. https://doi.org/10.1038/ncomms5006 CrossRefPubMed

5.

Court LE, Rao A, Krishnan S (2016) Radiomics in cancer diagnosis, cancer staging, and prediction of response to treatment. Translational cancer research 5 (4):337-339CrossRef

6.

Rutman AM, Kuo MD (2009) Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging. European journal of radiology 70 (2):232-241. https://doi.org/10.1016/j.ejrad.2009.01.050 CrossRefPubMed

7.

Kang J, Rancati T, Lee S, Oh JH, Kerns SL, Scott JG, Schwartz R, Kim S, Rosenstein BS (2018) Machine Learning and Radiogenomics: Lessons Learned and Future Directions. Frontiers in oncology 8:228. https://doi.org/10.3389/fonc.2018.00228 CrossRefPubMedPubMedCentral

8.

Peeken JC, Bernhofer M, Wiestler B, Goldberg T, Cremers D, Rost B, Wilkens JJ, Combs SE, Nusslin F (2018) Radiomics in radiooncology - Challenging the medical physicist. Physica medica: PM: an international journal devoted to the applications of physics to medicine and biology: official journal of the Italian Association of Biomedical Physics (AIFB) 48:27-36. https://doi.org/10.1016/j.ejmp.2018.03.012 CrossRef

9.

Park JE, Kim HS (2018) Radiomics as a Quantitative Imaging Biomarker: Practical Considerations and the Current Standpoint in Neuro-oncologic Studies. Nuclear medicine and molecular imaging 52 (2):99-108. https://doi.org/10.1007/s13139-017-0512-7 CrossRefPubMedPubMedCentral

10.

Zhang Y, Oikonomou A, Wong A, Haider MA, Khalvati F (2017) Radiomics-based Prognosis Analysis for Non-Small Cell Lung Cancer. Scientific reports 7:46349. https://doi.org/10.1038/srep46349 CrossRefPubMedPubMedCentral

11.

Shaikh F, Franc B, Allen E, Sala E, Awan O, Hendrata K, Halabi S, Mohiuddin S, Malik S, Hadley D, Shrestha R (2018) Translational Radiomics: Defining the Strategy Pipeline and Considerations for Application-Part 2: From Clinical Implementation to Enterprise. Journal of the American College of Radiology: JACR 15 (3 Pt B):543-549. https://doi.org/10.1016/j.jacr.2017.12.006

12.

Ger RB, Zhou S, Chi P-CM, Goff DL, Zhang L, Lee HJ, Fuller CD, Howell RM, Li H, Stafford RJ Quantitative image feature variability amongst CT scanners with a controlled scan protocol. In: Medical Imaging 2018: Computer-Aided Diagnosis, 2018. International Society for Optics and Photonics, p 105751O

13.

Kim H, Park CM, Lee M, Park SJ, Song YS, Lee JH, Hwang EJ, Goo JM (2016) Impact of reconstruction algorithms on CT radiomic features of pulmonary tumors: analysis of intra-and inter-reader variability and inter-reconstruction algorithm variability. PloS one 11 (10):e0164924CrossRefPubMedPubMedCentral

14.

Lu L, Ehmke RC, Schwartz LH, Zhao B (2016) Assessing agreement between radiomic features computed for multiple CT imaging settings. PloS one 11 (12):e0166550CrossRefPubMedPubMedCentral

15.

Paul R, Hawkins SH, Schabath MB, Gillies RJ, Hall LO, Goldgof DB (2018) Predicting malignant nodules by fusing deep features with classical radiomics features. Journal of medical imaging (Bellingham, Wash) 5 (1):011021. https://doi.org/10.1117/1.jmi.5.1.011021 CrossRef

16.

Afshar P, Mohammadi A, Plataniotis KN, Oikonomou A, Benali HJapa (2018) From Hand-Crafted to Deep Learning-based Cancer Radiomics: Challenges and Opportunities.

17.

Zhang B, He X, Ouyang F, Gu D, Dong Y, Zhang L, Mo X, Huang W, Tian J, Zhang SJCl (2017) Radiomic machine-learning classifiers for prognostic biomarkers of advanced nasopharyngeal carcinoma. 403:21-27

18.

Parmar C, Grossmann P, Bussink J, Lambin P, Aerts HJWL (2015) Machine Learning methods for Quantitative Radiomic Biomarkers. Scientific reports 5:13087. https://doi.org/10.1038/srep13087. https://www.nature.com/articles/srep13087#supplementary-information

19.

Parmar C, Grossmann P, Rietveld D, Rietbergen MM, Lambin P, Aerts HJJFio (2015) Radiomic machine-learning classifiers for prognostic biomarkers of head and neck cancer. 5:272

20.

Li Z, Wang Y, Yu J, Guo Y, Cao W (2017) Deep Learning based Radiomics (DLR) and its usage in noninvasive IDH1 prediction for low grade glioma. Scientific reports 7 (1):5467. https://doi.org/10.1038/s41598-017-05848-2 CrossRefPubMedPubMedCentral

21.

Chaunzwa TL, Christiani DC, Lanuti M, Shafer A, Diao N, Mak RH, Aerts H (2018) A deep-learning radiomics model for predicting survival in early-stage non-small cell lung cancer. 36 (15_suppl):8528-8528. https://doi.org/10.1200/jco.2018.36.15_suppl.8528

22.

Antropova N Deep Learning and Radiomics of Breast Cancer on DCE-MRI in Assessment of Malignancy and Response to Therapy.143. https://doi.org/10.6082/3jah-5j51

23.

Wang H, Cruz-Roa A, Basavanhally A, Gilmore H, Shih N, Feldman M, Tomaszewski J, Gonzalez F, Madabhushi A (2014) Mitosis detection in breast cancer pathology images by combining handcrafted and convolutional neural network features. Journal of medical imaging (Bellingham, Wash) 1 (3):034003. https://doi.org/10.1117/1.jmi.1.3.034003 CrossRef

24.

Aerts HJ (2016) The Potential of Radiomic-Based Phenotyping in Precision Medicine: A Review. JAMA oncology 2 (12):1636-1642. https://doi.org/10.1001/jamaoncol.2016.2631 CrossRefPubMed

25.

Kalra M, Wang G, Orton CGJMp (2018) Radiomics in lung cancer: Its time is here. 45 (3):997-1000

26.

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144 (5):646-674. https://doi.org/10.1016/j.cell.2011.02.013 CrossRefPubMed

27.

Berger MF, Mardis ER (2018) The emerging clinical relevance of genomics in cancer medicine. Nat Rev Clin Oncol 15 (6):353-365. https://doi.org/10.1038/s41571-018-0002-6 CrossRefPubMedPubMedCentral

28.

Pereira CB, Leal MF, de Souza CR, Montenegro RC, Rey JA, Carvalho AA, Assumpcao PP, Khayat AS, Pinto GR, Demachki S, de Arruda Cardoso Smith M, Burbano RR (2013) Prognostic and predictive significance of MYC and KRAS alterations in breast cancer from women treated with neoadjuvant chemotherapy. PloS one 8 (3):e60576. https://doi.org/10.1371/journal.pone.0060576 CrossRefPubMedPubMedCentral

29.

Cox J, Weinman S (2016) Mechanisms of doxorubicin resistance in hepatocellular carcinoma. Hepat Oncol 3 (1):57-59. https://doi.org/10.2217/hep.15.41 CrossRefPubMed

30.

Cheon DJ, Orsulic S (2014) Ten-gene biomarker panel: a new hope for ovarian cancer? Biomark Med 8 (4):523-526. https://doi.org/10.2217/bmm.14.16 CrossRefPubMed

31.

Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, Peters S (2019) Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol 30 (1):44-56. https://doi.org/10.1093/annonc/mdy495 CrossRefPubMed

32.

Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R (2017) Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther 16 (11):2598-2608. https://doi.org/10.1158/1535-7163.mct-17-0386 CrossRefPubMedPubMedCentral

33.

Efremova M, Finotello F, Rieder D, Trajanoski Z (2017) Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy. Front Immunol 8:1679. https://doi.org/10.3389/fimmu.2017.01679 CrossRefPubMedPubMedCentral

34.

Yarchoan M, Johnson BA, 3rd, Lutz ER, Laheru DA, Jaffee EM (2017) Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer 17 (4):209-222. https://doi.org/10.1038/nrc.2016.154 CrossRefPubMedPubMedCentral

35.

Diehn M, Nardini C, Wang DS, McGovern S, Jayaraman M, Liang Y, Aldape K, Cha S, Kuo MD (2008) Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci U S A 105 (13):5213-5218. https://doi.org/10.1073/pnas.0801279105 CrossRefPubMedPubMedCentral

36.

Colen RR, Mahajan B, Jolesz FA, Zinn PO (2011) Radiogenomic mapping in GBM in patients with high versus low edema/tumor infiltration using an image-genomic analysis of 12,764 genes and 555 micrornas. Neuro-oncology 3):iii142-iii143. doi:http://dx.doi.org/10.1093/neuonc/nor162

37.

Zinn PO, Mahajan B, Sathyan P, Singh SK, Majumder S, Jolesz FA, Colen RR (2011) Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme. PloS one 6 (10):e25451. https://doi.org/10.1371/journal.pone.0025451 CrossRefPubMedPubMedCentral

38.

Zhao L, Lee VH, Ng MK, Yan H, Bijlsma MFJBib (2018) Molecular subtyping of cancer: current status and moving toward clinical applications.

39.

Yang D, Rao G, Martinez J, Veeraraghavan A, Rao A (2015) Evaluation of tumor-derived MRI-texture features for discrimination of molecular subtypes and prediction of 12-month survival status in glioblastoma. Medical physics 42 (11):6725-6735. https://doi.org/10.1118/1.4934373 CrossRefPubMedPubMedCentral

40.

Czarnek NM, Clark K, Peters KB, Collins LM, Mazurowski MA Radiogenomics of glioblastoma: A pilot multi-institutional study to investigate a relationship between tumor shape features and tumor molecular subtype. In: Tourassi GD, Armato SG (eds), 2016. SPIE. https://doi.org/10.1117/12.2217084

41.

Mazurowski MA, Clark K, Czarnek NM, Shamsesfandabadi P, Peters KB, Saha A (2017) Radiogenomics of lower-grade glioma: algorithmically-assessed tumor shape is associated with tumor genomic subtypes and patient outcomes in a multi-institutional study with The Cancer Genome Atlas data. Journal of neuro-oncology 133 (1):27-35. https://doi.org/10.1007/s11060-017-2420-1 CrossRefPubMed

42.

Grossmann P, Gutman DA, Dunn WD, Jr., Holder CA, Aerts HJ (2016) Imaging-genomics reveals driving pathways of MRI derived volumetric tumor phenotype features in Glioblastoma. BMC cancer 16:611. https://doi.org/10.1186/s12885-016-2659-5 CrossRefPubMedPubMedCentral

43.

Gutman DA, Dunn WD, Jr., Grossmann P, Cooper LA, Holder CA, Ligon KL, Alexander BM, Aerts HJ (2015) Somatic mutations associated with MRI-derived volumetric features in glioblastoma. Neuroradiology 57 (12):1227-1237. https://doi.org/10.1007/s00234-015-1576-7 CrossRefPubMedPubMedCentral

44.

Gevaert O, Mitchell L, Achrol A, Xu J, Steinberg G, Cheshier S, Napel S, Zaharchuk G, Plevritis S (2013) Creating a radiogenomics map of multi-omics and quantitative image features in glioblastoma multiforme. Neuro-oncology 3):iii140-iii141. doi:http://dx.doi.org/10.1093/neuonc/not183

45.

Gevaert O, Mitchell LA, Achrol AS, Xu J, Echegaray S, Steinberg GK, Cheshier SH, Napel S, Zaharchuk G, Plevritis SK (2014) Glioblastoma multiforme: exploratory radiogenomic analysis by using quantitative image features. Radiology 273 (1):168-174. https://doi.org/10.1148/radiol.14131731 CrossRefPubMed

46.

Zinn PO, Singh SK, Kotrotsou A, Abrol S, Thomas G, Mosley J, Elakkad A, Hassan I, Kumar A, Colen RR (2017) Distinct Radiomic Phenotypes Define Glioblastoma TP53-PTEN-EGFR Mutational Landscape. Neurosurgery 64 (CN_suppl_1):203-210. https://doi.org/10.1093/neuros/nyx316

47.

Hu LS, Ning S, Eschbacher JM, Baxter LC, Gaw N, Ranjbar S, Plasencia J, Dueck AC, Peng S, Smith KA, Nakaji P, Karis JP, Quarles CC, Wu T, Loftus JC, Jenkins RB, Sicotte H, Kollmeyer TM, O’Neill BP, Elmquist W, Hoxworth JM, Frakes D, Sarkaria J, Swanson KR, Tran NL, Li J, Mitchell JR (2017) Radiogenomics to characterize regional genetic heterogeneity in glioblastoma. Neuro-oncology 19 (1):128-137. https://doi.org/10.1093/neuonc/now135 CrossRefPubMed

48.

Hassan I, Kotrotsou A, Matsuoka CK, Alfaro-Munoz K, Elshafeey N, Zinn P, De Groot J, Colen R (2017) Increased mutation burden (Hypermutation) in gliomas is associated with a unique radiomic texture signature in magnetic resonance imaging. Neuro-oncology 19 (Supplement 6):vi147-vi148. doi:http://dx.doi.org/10.1093/neuonc/nox168

49.

Miller JJ, Shih HA, Andronesi OC, Cahill DP (2017) Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications. Cancer 123 (23):4535-4546. https://doi.org/10.1002/cncr.31039 CrossRefPubMed

50.

Wang Y, Zhang T, Li S, Fan X, Ma J, Wang L, Jiang T (2015) Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas. European journal of neurology 22 (2):348-354. https://doi.org/10.1111/ene.12578 CrossRefPubMed

51.

Eichinger P, Alberts E, Delbridge C, Trebeschi S, Valentinitsch A, Bette S, Huber T, Gempt J, Meyer B, Schlegel J, Zimmer C, Kirschke JS, Menze BH, Wiestler B (2017) Diffusion tensor image features predict IDH genotype in newly diagnosed WHO grade II/III gliomas. Scientific reports 7 (1):13396. https://doi.org/10.1038/s41598-017-13679-4 CrossRefPubMedPubMedCentral

52.

Hsieh KL, Chen CY, Lo CM (2017) Radiomic model for predicting mutations in the isocitrate dehydrogenase gene in glioblastomas. Oncotarget 8 (28):45888-45897. https://doi.org/10.18632/oncotarget.17585 CrossRefPubMedPubMedCentral

53.

Lohmann P, Lerche C, Bauer E, Steger J, Stoffels G, Filss CP, Stegmayr C, Neumaier B, Shah NJ, Langen K, Galldiks N (2017) Predicting isocitrate dehydrogenase genotype in malignant glioma using fet pet radiomics. Neuro-oncology 19 (Supplement 3):iii88-iii89. doi:http://dx.doi.org/10.1093/neuonc/nox036

54.

Lohmann P, Lerche C, Bauer EK, Steger J, Stoffels G, Blau T, Dunkl V, Kocher M, Viswanathan S, Filss CP, Stegmayr C, Neumaier B, Shah NJ, Fink GR, Langen KJ, Galldiks N (2018) Radiomics for prediction of the IDH genotype in gliomas. NuklearMedizin 57 (2):A36. doi:http://dx.doi.org/10.1055/s00839473 CrossRef

55.

Bisdas S, Shen H, Thust S, Katsaros V, Stranjalis G, Boskos C, Brandner S, Zhang J (2018) Texture analysis- and support vector machine-assisted diffusional kurtosis imaging may allow in vivo gliomas grading and IDH-mutation status prediction: a preliminary study. Scientific reports 8 (1):6108. https://doi.org/10.1038/s41598-018-24438-4 CrossRefPubMedPubMedCentral

56.

Hong EK, Choi SH, Shin DJ, Jo SW, Yoo RE, Kang KM, Yun TJ, Kim JH, Sohn CH, Park SH, Won JK, Kim TM, Park CK, Kim IH, Lee ST (2018) Radiogenomics correlation between MR imaging features and major genetic profiles in glioblastoma. European radiology. https://doi.org/10.1007/s00330-018-5400-8

57.

Zhang X, Tian Q, Wu YX, Xu XP, Li BJ, Liu YX, Liu Y, Lu HB IDH mutation assessment of glioma using texture features of multimodal MR images. In: Petrick NA, Armato SG (eds), 2017. SPIE. https://doi.org/10.1117/12.2254212

58.

Arita H, Kinoshita M, Kawaguchi A, Takahashi M, Narita Y, Terakawa Y, Tsuyuguchi N, Okita Y, Nonaka M, Moriuchi S, Takagaki M, Fujimoto Y, Fukai J, Izumoto S, Ishibashi K, Nakajima Y, Shofuda T, Kanematsu D, Yoshioka E, Kodama Y, Mano M, Mori K, Ichimura K, Kanemura Y (2018) Lesion location implemented magnetic resonance imaging radiomics for predicting IDH and TERT promoter mutations in grade II/III gliomas. Scientific reports 8 (1):11773. https://doi.org/10.1038/s41598-018-30273-4 CrossRefPubMedPubMedCentral

59.

Jakola AS, Zhang YH, Skjulsvik AJ, Solheim O, Bo HK, Berntsen EM, Reinertsen I, Gulati S, Forander P, Brismar TB (2018) Quantitative texture analysis in the prediction of IDH status in low-grade gliomas. Clinical neurology and neurosurgery 164:114-120. https://doi.org/10.1016/j.clineuro.2017.12.007 CrossRefPubMed

60.

Papp L, Poetsch N, Grahovac M, Mitterhauser M, Wadsak W, Beyer T, Hacker M, Traub-Weidinger T (2018) Prediction of IDH1-R132H mutation status of glioma patients from 11-C-Methionine-PET radiomics features utilizing machine learning approaches. NuklearMedizin 57 (2):A78. doi:http://dx.doi.org/10.1055/s00839473 CrossRef

61.

Zhang X, Tian Q, Wang L, Liu Y, Li B, Liang Z, Gao P, Zheng K, Zhao B, Lu H (2018) Radiomics Strategy for Molecular Subtype Stratification of Lower-Grade Glioma: Detecting IDH and TP53 Mutations Based on Multimodal MRI. Journal of magnetic resonance imaging: JMRI. https://doi.org/10.1002/jmri.25960

62.

Shofty B, Artzi M, Ben Bashat D, Liberman G, Haim O, Kashanian A, Bokstein F, Blumenthal DT, Ram Z, Shahar T (2018) MRI radiomics analysis of molecular alterations in low-grade gliomas. International journal of computer assisted radiology and surgery 13 (4):563-571. https://doi.org/10.1007/s11548-017-1691-5 CrossRefPubMed

63.

Van Der Voort SR, Gahrmann R, Van Den Bent MJ, Vincent AJPE, Niessen WJ, Smits M, Klein S Radiogenomic classification of the 1p/19q status in presumed low-grade gliomas. In, 2017. IEEE Computer Society, pp 638-641. https://doi.org/10.1109/isbi.2017.7950601

64.

Yu J, Shi Z, Lian Y, Li Z, Liu T, Gao Y, Wang Y, Chen L, Mao Y (2017) Noninvasive IDH1 mutation estimation based on a quantitative radiomics approach for grade II glioma. European radiology 27 (8):3509-3522. https://doi.org/10.1007/s00330-016-4653-3 CrossRefPubMed

65.

Zhou H, Vallieres M, Bai HX, Su C, Tang H, Oldridge D, Zhang Z, Xiao B, Liao W, Tao Y, Zhou J, Zhang P, Yang L (2017) MRI features predict survival and molecular markers in diffuse lower-grade gliomas. Neuro-oncology 19 (6):862-870. https://doi.org/10.1093/neuonc/now256 CrossRefPubMedPubMedCentral

66.

Boots-Sprenger SHE, Sijben A, Rijntjes J, Tops BBJ, Idema AJ, Rivera AL, Bleeker FE, Gijtenbeek AM, Diefes K, Heathcock L, Aldape KD, Jeuken JWM, Wesseling P (2013) Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution. Modern Pathology 26:922. https://doi.org/10.1038/modpathol.2012.166 CrossRefPubMed

67.

Li Y, Liu X, Xu K, Qian Z, Wang K, Fan X, Li S, Wang Y, Jiang T (2018) MRI features can predict EGFR expression in lower grade gliomas: A voxel-based radiomic analysis. European radiology 28 (1):356-362. https://doi.org/10.1007/s00330-017-4964-z CrossRefPubMed

68.

Kickingereder P, Bonekamp D, Nowosielski M, Kratz A, Sill M, Burth S, Wick A, Eidel O, Schlemmer HP, Radbruch A, Debus J, Herold-Mende C, Unterberg A, Jones D, Pfister S, Wick W, von Deimling A, Bendszus M, Capper D (2016) Radiogenomics of Glioblastoma: Machine Learning-based Classification of Molecular Characteristics by Using Multiparametric and Multiregional MR Imaging Features. Radiology 281 (3):907-918. https://doi.org/10.1148/radiol.2016161382 CrossRefPubMed

69.

Akbari H, Bakas S, Pisapia JM, Nasrallah MP, Rozycki M, Martinez-Lage M, Morrissette JJD, Dahmane N, O’Rourke DM, Davatzikos C (2018) In vivo evaluation of EGFRvIII mutation in primary glioblastoma patients via complex multiparametric MRI signature. Neuro-oncology 20 (8):1068-1079. https://doi.org/10.1093/neuonc/noy033 CrossRefPubMedPubMedCentral

70.

Lee J, Narang S, Martinez JJ, Rao G, Rao A (2015) Associating spatial diversity features of radiologically defined tumor habitats with epidermal growth factor receptor driver status and 12-month survival in glioblastoma: methods and preliminary investigation. Journal of medical imaging (Bellingham, Wash) 2 (4):041006. https://doi.org/10.1117/1.jmi.2.4.041006 CrossRef

71.

Cho H, Hong B, Park C, Park S, Choi S (2017) Is BCAT1 a new MR imaging-related biomarker for prognosis prediction in IDH1-wildtype glioblastoma patients?: Radiogenomics study. Neuro-oncology 19 (Supplement 3):iii41. doi:http://dx.doi.org/10.1093/neuonc/nox036

72.

Maraka S, Kotrotsou A, Abrol S, Hassan A, Elshafeey N, Starostina O, Alfaro-Munoz K, Colen R, De Groot J (2017) Radiomic analysis on apparent diffusion coefficient (ADC) maps predicts platelet-derived growth factor receptor alpha (PDGFRA) gene amplification for newly diagnosed glioblastoma patients. Neuro-oncology 19 (Supplement 6):vi148. doi:http://dx.doi.org/10.1093/neuonc/nox168

73.

Li Y, Liu X, Qian Z, Sun Z, Xu K, Wang K, Fan X, Zhang Z, Li S, Wang Y, Jiang T (2018) Genotype prediction of ATRX mutation in lower-grade gliomas using an MRI radiomics signature. European radiology 28 (7):2960-2968. https://doi.org/10.1007/s00330-017-5267-0 CrossRefPubMed

74.

Beig N, Patel J, Prasanna P, Partovi S, Varadan V, Madabhushi A, Tiwari P Radiogenomic analysis of hypoxia pathway reveals computerized MRI descriptors predictive of overall survival in glioblastoma. In: Petrick NA, Armato SG (eds), 2017. SPIE. https://doi.org/10.1117/12.2255694

75.

Li Y, Qian Z, Xu K, Wang K, Fan X, Li S, Liu X, Wang Y, Jiang T (2017) Radiomic features predict Ki-67 expression level and survival in lower grade gliomas. Journal of neuro-oncology 135 (2):317-324. https://doi.org/10.1007/s11060-017-2576-8 CrossRefPubMed

76.

Jeon H, Cho HR, Park CK, Park SH, Kumarir N, Thakur N, Chung J, Choi SH (2017) CD49D correlated with apparent diffusion coefficient as a promising biomarker for prognosis prediction of glioblastoma: Radiogenomics study. Neuro-oncology 19 (Supplement 6):vi157. doi:http://dx.doi.org/10.1093/neuonc/nox168

77.

Narang S, Kim D, Aithala S, Heimberger AB, Ahmed S, Rao D, Rao G, Rao A (2017) Tumor image-derived texture features are associated with CD3 T-cell infiltration status in glioblastoma. Oncotarget 8 (60):101244-101254. https://doi.org/10.18632/oncotarget.20643 CrossRefPubMedPubMedCentral

78.

Lehrer M, Bhadra A, Ravikumar V, Chen JY, Wintermark M, Hwang SN, Holder CA, Huang EP, Fevrier-Sullivan B, Freymann JB, Rao A (2017) Multiple-response regression analysis links magnetic resonance imaging features to de-regulated protein expression and pathway activity in lower grade glioma. Oncoscience 4 (5-6):57-66. https://doi.org/10.18632/oncoscience.353 CrossRefPubMedPubMedCentral

79.

Rathore S, Akbari H, Rozycki M, Abdullah KG, Nasrallah MP, Binder ZA, Davuluri RV, Lustig RA, Dahmane N, Bilello M, O’Rourke DM, Davatzikos C (2018) Radiomic MRI signature reveals three distinct subtypes of glioblastoma with different clinical and molecular characteristics, offering prognostic value beyond IDH1. Scientific reports 8 (1):5087. https://doi.org/10.1038/s41598-018-22739-2 CrossRefPubMedPubMedCentral

80.

Li ZC, Bai H, Sun Q, Li Q, Liu L, Zou Y, Chen Y, Liang C, Zheng H (2018) Multiregional radiomics features from multiparametric MRI for prediction of MGMT methylation status in glioblastoma multiforme: A multicentre study. European radiology 28 (9):3640-3650. https://doi.org/10.1007/s00330-017-5302-1 CrossRefPubMed

81.

Bi WL, Corroller T, Greenwald NF, Huynh E, Aizer MAA, Santagata S, Al-Mefty O, Alexander B, Dunn IF, Huang R, Aerts H (2017) Radiographic prediction of meningioma grade and genomic profile. Journal of Neurological Surgery Part B: Skull Base Conference: 27th Annual Meeting North American Skull Base Society United States 78 (Supplement 1). doi:http://dx.doi.org/10.1055/s-0037-1600633

82.

Coroller T, Bi W, Greenwald N, Zeleznik R, Huynh E, Parmar C, Huang R, Aerts H (2018) Predicting meningioma tumor recurrence using radiogenomics data. Medical physics 45 (6):e678. doi:http://dx.doi.org/10.1002/mp.12938 CrossRef

83.

Dasgupta A, Gupta T, Pungavkar S, Janu A, Shirsat N, Chinnaswamy G, Jalali R (2014) Can we predict molecular subtypes of medulloblastoma based on MRI? Encouraging data from a blinded study. Journal of Cancer Research and Therapeutics 1):S5-S6

84.

Brisse HJ, Blanc T, Schleiermacher G, Mosseri V, Philippe-Chomette P, Janoueix-Lerosey I, Pierron G, Lapouble E, Peuchmaur M, Freneaux P, Galmiche L, Algret N, Peycelon M, Michon J, Delattre O, Sarnacki S (2017) Radiogenomics of neuroblastomas: Relationships between imaging phenotypes, tumor genomic profile and survival. PloS one 12 (9):e0185190. https://doi.org/10.1371/journal.pone.0185190 CrossRefPubMedPubMedCentral

85.

Sun YW, Xu J, Zhou J, Liu WJ (2018) Targeted drugs for systemic therapy of lung cancer with brain metastases. Oncotarget 9 (4):5459-5472. https://doi.org/10.18632/oncotarget.23616 CrossRefPubMed

86.

Chan BA, Hughes BG (2015) Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res 4 (1):36-54. https://doi.org/10.3978/j.issn.2218-6751.2014.05.01 CrossRefPubMedPubMedCentral

87.

Roman M, Baraibar I, Lopez I, Nadal E, Rolfo C, Vicent S, Gil-Bazo I (2018) KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target. Mol Cancer 17 (1):33. https://doi.org/10.1186/s12943-018-0789-x CrossRefPubMedPubMedCentral

88.

De Jong EEC, Van Elmpt W, Hendriks LEL, Leijenaar RTH, Dingemans AMC, Lambin P (2016) Radiomic CT features for evaluation of EGFR and KRAS mutation status in patients with advanced NSCLC. Radiotherapy and Oncology 119 (Supplement 1):S290-S291CrossRef

89.

Dagogo-Jack I, Shaw ATJTo (2016) Screening for ALK rearrangements in lung cancer: time for a new generation of diagnostics? 21 (6):662-663

90.

Gevaert O, Xu J, Hoang CD, Leung AN, Xu Y, Quon A, Rubin DL, Napel S, Plevritis SK (2012) Non-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data--methods and preliminary results. Radiology 264 (2):387-396. https://doi.org/10.1148/radiol.12111607 CrossRefPubMedPubMedCentral

91.

Halpenny DF, Riely GJ, Hayes S, Yu H, Zheng J, Moskowitz CS, Ginsberg MS (2014) Are there imaging characteristics associated with lung adenocarcinomas harboring ALK rearrangements? Lung cancer (Amsterdam, Netherlands) 86 (2):190-194. https://doi.org/10.1016/j.lungcan.2014.09.007 CrossRef

92.

Yoon HJ, Sohn I, Cho JH, Lee HY, Kim JH, Choi YL, Kim H, Lee G, Lee KS, Kim J (2015) Decoding Tumor Phenotypes for ALK, ROS1, and RET Fusions in Lung Adenocarcinoma Using a Radiomics Approach. Medicine 94 (41):e1753. https://doi.org/10.1097/md.0000000000001753 CrossRefPubMedPubMedCentral

93.

Caramella C, Bluthgen MV, Rosellini S, Leduc C, Facchinetti F, Haspinger E, Ferte C, Michiels S, Soria JC, Besse B (2015) Prognostic value of texture analysis and correlation with molecular profile in EGFR mutated/ALK rearranged advanced non-small cell lung cancer (NSCLC). European Journal of Cancer 3):S647-S648

94.

Aerts HJ, Grossmann P, Tan Y, Oxnard GR, Rizvi N, Schwartz LH, Zhao B (2016) Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC. Scientific reports 6:33860. https://doi.org/10.1038/srep33860 CrossRefPubMedPubMedCentral

95.

Weiss GJ, Ganeshan B, Miles KA, Campbell DH, Cheung PY, Frank S, Korn RL (2014) Noninvasive image texture analysis differentiates K-ras mutation from pan-wildtype NSCLC and is prognostic. PloS one 9 (7):e100244. https://doi.org/10.1371/journal.pone.0100244 CrossRefPubMedPubMedCentral

96.

Rizzo S, Petrella F, Buscarino V, De Maria F, Raimondi S, Barberis M, Fumagalli C, Spitaleri G, Rampinelli C, De Marinis F, Spaggiari L, Bellomi M (2016) CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer. European radiology 26 (1):32-42. https://doi.org/10.1007/s00330-015-3814-0 CrossRefPubMed

97.

Lv J, Zhang H, Ma J, Ma Y, Gao G, Song Z, Yang Y (2018) Comparison of CT radiogenomic and clinical characteristics between EGFR and KRAS mutations in lung adenocarcinomas. Clinical radiology 73 (6):590.e591-590.e598. https://doi.org/10.1016/j.crad.2018.01.009 CrossRef

98.

Sorensen J, Erasmus Jr J, Shroff G, Rao A, Stingo F, Court L, Gold KA, Lee J, Heymach JV, Swisher S, Godoy M (2015) Combining CT texture analysis with semantic imaging descriptions for the radiogenomic detection of EGFR and KRAS mutations in NSCLC. Journal of Thoracic Oncology 2):S700

99.

Rios Velazquez E, Parmar C, Liu Y, Coroller TP, Cruz G, Stringfield O, Ye Z, Makrigiorgos M, Fennessy F, Mak RH, Gillies R, Quackenbush J, Aerts H (2017) Somatic Mutations Drive Distinct Imaging Phenotypes in Lung Cancer. Cancer research 77 (14):3922-3930. https://doi.org/10.1158/0008-5472.can-17-0122 CrossRefPubMed

100.

Yip SSF, Parmar C, Kim J, Huynh E, Mak RH, Aerts H (2017) Impact of experimental design on PET radiomics in predicting somatic mutation status. European journal of radiology 97:8-15. https://doi.org/10.1016/j.ejrad.2017.10.009 CrossRefPubMed

101.

Yip SS, Kim J, Coroller TP, Parmar C, Velazquez ER, Huynh E, Mak RH, Aerts HJ (2017) Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non-Small Cell Lung Cancer. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 58 (4):569-576. https://doi.org/10.2967/jnumed.116.181826 CrossRef

102.

Kim TJ, Lee CT, Jheon SH, Park JS, Chung JH (2016) Radiologic Characteristics of Surgically Resected Non-Small Cell Lung Cancer With ALK Rearrangement or EGFR Mutations. The Annals of thoracic surgery 101 (2):473-480. https://doi.org/10.1016/j.athoracsur.2015.07.062 CrossRefPubMed

103.

Sawan P, Plodkowski AJ, Li AE, Li BT, Drilon A, Capanu M, Ginsberg MS (2018) CT features of HER2-mutant lung adenocarcinomas. Clinical imaging 51:279-283. https://doi.org/10.1016/j.clinimag.2018.05.028 CrossRefPubMedPubMedCentral

104.

Halpenny DF, Plodkowski A, Riely G, Zheng J, Litvak A, Moscowitz C, Ginsberg MS (2017) Radiogenomic evaluation of lung cancer - Are there imaging characteristics associated with lung adenocarcinomas harboring BRAF mutations? Clinical imaging 42:147-151. https://doi.org/10.1016/j.clinimag.2016.11.015 CrossRefPubMed

105.

Ozkan E, West A, Dedelow JA, Chu BF, Zhao W, Yildiz VO, Otterson GA, Shilo K, Ghosh S, King M, White RD, Erdal BS (2015) CT Gray-Level Texture Analysis as a Quantitative Imaging Biomarker of Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma of the Lung. AJR American journal of roentgenology 205 (5):1016-1025. https://doi.org/10.2214/ajr.14.14147 CrossRefPubMed

106.

Moon H, Choi JH, Park JH, Byun BH, Lim I, Kim BI, Choi CW, Lim SM (2015) Differences of < sup > 18 </sup > F-FDG PET tumor texture parameters according to the presence of epidermal growth factor receptor mutation in non-small cell lung cancer. Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI 56 (SUPPL. 3)

107.

Zhou M, Leung A, Echegaray S, Gentles A, Shrager JB, Jensen KC, Berry GJ, Plevritis SK, Rubin DL, Napel S, Gevaert O (2018) Non-Small Cell Lung Cancer Radiogenomics Map Identifies Relationships between Molecular and Imaging Phenotypes with Prognostic Implications. Radiology 286 (1):307-315. https://doi.org/10.1148/radiol.2017161845 CrossRefPubMed

108.

Gevaert O, Echegaray S, Khuong A, Hoang CD, Shrager JB, Jensen KC, Berry GJ, Guo HH, Lau C, Plevritis SK, Rubin DL, Napel S, Leung AN (2017) Predictive radiogenomics modeling of EGFR mutation status in lung cancer. Scientific reports 7:41674. https://doi.org/10.1038/srep41674 CrossRefPubMedPubMedCentral

109.

Sacconi B, Anzidei M, Leonardi A, Boni F, Saba L, Scipione R, Anile M, Rengo M, Longo F, Bezzi M, Venuta F, Napoli A, Laghi A, Catalano C (2017) Analysis of CT features and quantitative texture analysis in patients with lung adenocarcinoma: a correlation with EGFR mutations and survival rates. Clinical radiology 72 (6):443-450. https://doi.org/10.1016/j.crad.2017.01.015 CrossRefPubMed

110.

Rios Velazquez E, Liu Y, Parmar C, Narayan V, Gillies R, Aerts H (2016) Radiomic CT features complement semantic annotations to predict EGFR mutations in lung adenocarcinomas. Medical physics 43 (6 PART2):3706

111.

Jia T, Xiong J, Li X, Ma J, Ren Y, Xu Z, Cai X, Zhang J, Zhao J, Fu X (2017) Detecting epidermal growth factor receptor mutation status in patients with lung adenocarcinoma using radiomics and random forest. Journal of Thoracic Oncology 12 (11 Supplement 2):S1860

112.

Clay R, Johnson T, Bartholmai BJ, Karwoski R, Maldonado F, Rajagopalan S, Peikert T (2018) Canary (computer aided nodule analysis and risk yield) as a radiologic biomarker to predict tumor response to EGFR-targeted therapy in adenocarcinoma of the lung. American Journal of Respiratory and Critical Care Medicine Conference: American Thoracic Society International Conference, ATS 197 (MeetingAbstracts)

113.

Zhang L, Chen B, Liu X, Song J, Fang M, Hu C, Dong D, Li W, Tian J (2018) Quantitative Biomarkers for Prediction of Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Cancer. Translational oncology 11 (1):94-101. https://doi.org/10.1016/j.tranon.2017.10.012 CrossRefPubMed

114.

Grossmann P, Stringfield O, El-Hachem N, Bui MM, Rios Velazquez E, Parmar C, Leijenaar RT, Haibe-Kains B, Lambin P, Gillies RJ, Aerts HJ (2017) Defining the biological basis of radiomic phenotypes in lung cancer. eLife 6. https://doi.org/10.7554/elife.23421

115.

Emaminejad N, Qian W, Guan Y, Tan M, Qiu Y, Liu H, Zheng B (2016) Fusion of Quantitative Image and Genomic Biomarkers to Improve Prognosis Assessment of Early Stage Lung Cancer Patients. IEEE Trans Biomed Eng 63 (5):1034-1043. https://doi.org/10.1109/tbme.2015.2477688 CrossRefPubMed

116.

Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, Jong RA, Hislop G, Chiarelli A, Minkin S, Yaffe MJ (2007) Mammographic density and the risk and detection of breast cancer. N Engl J Med 356 (3):227-236. https://doi.org/10.1056/nejmoa062790 CrossRefPubMed

117.

McCormack VA, dos Santos Silva I (2006) Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15 (6):1159-1169. https://doi.org/10.1158/1055-9965.epi-06-0034 CrossRefPubMed

118.

Li H, Giger ML, Lan L, Yuan Y, Bhooshan N, Olopade OI Effect of variable gain on computerized texture analysis on digitalized mammograms. In: Summers RM, Karssemeijer N (eds), 2010. SPIE. https://doi.org/10.1117/12.845321

119.

Gierach GL, Li H, Loud JT, Greene MH, Chow CK, Lan L, Prindiville SA, Eng-Wong J, Soballe PW, Giambartolomei C, Mai PL, Galbo CE, Nichols K, Calzone KA, Olopade OI, Gail MH, Giger ML (2014) Relationships between computer-extracted mammographic texture pattern features and BRCA1/2 mutation status: a cross-sectional study. Breast cancer research: BCR 16 (4):424. https://doi.org/10.1186/preaccept-1744229618121391. https://doi.org/10.1186/s13058-014-0424-8 CrossRefPubMedPubMedCentral

120.

Li H, Giger ML, Lan L, Janardanan J, Sennett CA (2014) Comparative analysis of image-based phenotypes of mammographic density and parenchymal patterns in distinguishing between BRCA1/2 cases, unilateral cancer cases, and controls. Journal of medical imaging (Bellingham, Wash) 1 (3):031009. https://doi.org/10.1117/1.jmi.1.3.031009 CrossRef

121.

Li H, Giger ML, Huynh BQ, Antropova NO (2017) Deep learning in breast cancer risk assessment: evaluation of convolutional neural networks on a clinical dataset of full-field digital mammograms. Journal of medical imaging (Bellingham, Wash) 4 (4):041304. https://doi.org/10.1117/1.jmi.4.4.041304 CrossRef

122.

Yamamoto S, Maki DD, Korn RL, Kuo MD (2012) Radiogenomic analysis of breast cancer using MRI: a preliminary study to define the landscape. AJR American journal of roentgenology 199 (3):654-663. https://doi.org/10.2214/ajr.11.7824 CrossRefPubMed

123.

Lee CH, Dershaw DD, Kopans D, Evans P, Monsees B, Monticciolo D, Brenner RJ, Bassett L, Berg W, Feig S (2010) Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. Journal of the American college of radiology 7 (1):18-27CrossRefPubMed

124.

Haspinger ER, Rosellini S, Ammari S, Dercle L, Bluthgen MV, Besse B, Caramella C, Massard C, Lacroix L, De Baere T, Deschamps F, Michiels S, Soria JC, Ferte C (2015) Radiomics to identify HER2 amplification or mutation in metastatic patients with solid tumors prospectively enrolled in MOSCATO-01. European Journal of Cancer 3):S101CrossRef

125.

Mazurowski MA, Zhang J, Grimm LJ, Yoon SC, Silber JI (2014) Radiogenomic analysis of breast cancer: luminal B molecular subtype is associated with enhancement dynamics at MR imaging. Radiology 273 (2):365-372. https://doi.org/10.1148/radiol.14132641 CrossRefPubMed

126.

Grimm LJ, Zhang J, Mazurowski MA (2015) Computational approach to radiogenomics of breast cancer: Luminal A and luminal B molecular subtypes are associated with imaging features on routine breast MRI extracted using computer vision algorithms. Journal of magnetic resonance imaging: JMRI 42 (4):902-907. https://doi.org/10.1002/jmri.24879 CrossRefPubMed

127.

Wang S, Fan M, Zhang J, Zheng B, Wang X, Li L Radiogenomic analysis of breast cancer: Dynamic contrast enhanced - Magnetic resonance imaging based features are associated with molecular subtypes. In: Cook TS, Zhang J (eds), 2016. SPIE. https://doi.org/10.1117/12.2217658

128.

Saha A, Harowicz MR, Grimm LJ, Kim CE, Ghate SV, Walsh R, Mazurowski MA (2018) A machine learning approach to radiogenomics of breast cancer: a study of 922 subjects and 529 DCE-MRI features. British journal of cancer. https://doi.org/10.1038/s41416-018-0185-8

129.

Wu J, Li B, Sun X, Cao G, Rubin DL, Napel S, Ikeda DM, Kurian AW, Li R (2017) Heterogeneous Enhancement Patterns of Tumor-adjacent Parenchyma at MR Imaging Are Associated with Dysregulated Signaling Pathways and Poor Survival in Breast Cancer. Radiology 285 (2):401-413. https://doi.org/10.1148/radiol.2017162823 CrossRefPubMed

130.

Zhu Y, Li H, Guo W, Drukker K, Lan L, Giger ML, Ji Y (2015) Deciphering Genomic Underpinnings of Quantitative MRI-based Radiomic Phenotypes of Invasive Breast Carcinoma. Scientific reports 5:17787. https://doi.org/10.1038/srep17787 CrossRefPubMedPubMedCentral

131.

Li H, Zhu Y, Burnside ES, Drukker K, Hoadley KA, Fan C, Conzen SD, Whitman GJ, Sutton EJ, Net JM, Ganott M, Huang E, Morris EA, Perou CM, Ji Y, Giger ML (2016) MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays. Radiology 281 (2):382-391. https://doi.org/10.1148/radiol.2016152110 CrossRefPubMed

132.

Hutchinson L (2013) CLOVAR validates prognostic gene-expression signature. Nat Rev Clin Oncol 10:68. https://doi.org/10.1038/nrclinonc.2013.2 CrossRefPubMed

133.

Winterhoff B, Hamidi H, Wang C, Kalli KR, Fridley BL, Dering J, Chen H-W, Cliby WA, Wang H-J, Dowdy SJGo (2016) Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures. 141 (1):95-100

134.

Vargas HA, Huang EP, Lakhman Y, Ippolito JE, Bhosale P, Mellnick V, Shinagare AB, Anello M, Kirby J, Fevrier-Sullivan BJR (2017) Radiogenomics of high-grade serous ovarian cancer: multireader multi-institutional study from the Cancer Genome Atlas Ovarian Cancer Imaging Research Group. 285 (2):482-492

135.

Anuradha S, Webb PM, Blomfield P, Brand AH, Friedlander M, Leung Y, Obermair A, Oehler MK, Quinn M, Steer CJMJoA (2014) Survival of Australian women with invasive epithelial ovarian cancer: a population‐based study. 201 (5):283-288

136.

Lu H, Arshad M, Thornton A, Avesani G, Cunnea P, Curry E, Kanavati F, Liang J, Nixon K, Williams STJNc (2019) A mathematical-descriptor of tumor-mesoscopic-structure from computed-tomography images annotates prognostic-and molecular-phenotypes of epithelial ovarian cancer. 10 (1):764

137.

Tamez-Pena JG, Rodriguez-Rojas JA, Gomez-Rueda H, Celaya-Padilla JM, Rivera-Prieto RA, Palacios-Corona R, Garza-Montemayor M, Cardona-Huerta S, Trevino V (2018) Radiogenomics analysis identifies correlations of digital mammography with clinical molecular signatures in breast cancer. PloS one 13 (3):e0193871. https://doi.org/10.1371/journal.pone.0193871 CrossRefPubMedPubMedCentral

138.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68 (6):394-424. https://doi.org/10.3322/caac.21492 CrossRefPubMed

139.

Tam K (2013) The roles of doxorubicin in hepatocellular carcinoma. ADMET and DMPK 1 (3):29-44CrossRef

140.

Kuo MD, Gollub J, Sirlin CB, Ooi C, Chen X (2007) Radiogenomic analysis to identify imaging phenotypes associated with drug response gene expression programs in hepatocellular carcinoma. Journal of vascular and interventional radiology: JVIR 18 (7):821-831. https://doi.org/10.1016/j.jvir.2007.04.031 CrossRefPubMed

141.

West DL, Kotrotsou A, Niekamp AS, Idris T, Camejo DG, Mazal NJ, Cardenas NJ, Goldberg JL, Colen RR (2017) CT-based radiomic analysis of hepatocellular carcinoma patients to predict key genomic information. Journal of Clinical Oncology Conference 35 (15 Supplement 1)

142.

Lim KC, Chow PK, Allen JC, Chia GS, Lim M, Cheow PC, Chung AY, Ooi LL, Tan SB (2011) Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. Annals of surgery 254 (1):108-113. https://doi.org/10.1097/sla.0b013e31821ad884 CrossRefPubMed

143.

Chou CT, Chen RC, Lee CW, Ko CJ, Wu HK, Chen YL (2012) Prediction of microvascular invasion of hepatocellular carcinoma by pre-operative CT imaging. The British journal of radiology 85 (1014):778-783. https://doi.org/10.1259/bjr/65897774 CrossRefPubMedPubMedCentral

144.

Chandarana H, Robinson E, Hajdu CH, Drozhinin L, Babb JS, Taouli B (2011) Microvascular invasion in hepatocellular carcinoma: is it predictable with pretransplant MRI? AJR American journal of roentgenology 196 (5):1083-1089. https://doi.org/10.2214/ajr.10.4720 CrossRefPubMed

145.

Segal E, Sirlin CB, Ooi C, Adler AS, Gollub J, Chen X, Chan BK, Matcuk GR, Barry CT, Chang HY, Kuo MD (2007) Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol 25 (6):675-680. https://doi.org/10.1038/nbt1306 CrossRefPubMed

146.

Banerjee S, Wang DS, Kim HJ, Sirlin CB, Chan MG, Korn RL, Rutman AM, Siripongsakun S, Lu D, Imanbayev G, Kuo MD (2015) A computed tomography radiogenomic biomarker predicts microvascular invasion and clinical outcomes in hepatocellular carcinoma. Hepatology (Baltimore, Md) 62 (3):792-800. https://doi.org/10.1002/hep.27877 CrossRef

147.

Tang H, Bai HX, Su C, Lee AM, Yang L (2016) The effect of cirrhosis on radiogenomic biomarker’s ability to predict microvascular invasion and outcome in hepatocellular carcinoma. Hepatology (Baltimore, Md) 64 (2):691-692. https://doi.org/10.1002/hep.28620 CrossRef

148.

Simonetti RG, Camma C, Fiorello F, Politi F, D’Amico G, Pagliaro L (1991) Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci 36 (7):962-972

149.

Davis GL, Dempster J, Meler JD, Orr DW, Walberg MW, Brown B, Berger BD, O’Connor JK, Goldstein RM (2008) Hepatocellular carcinoma: management of an increasingly common problem. Proc (Bayl Univ Med Cent) 21 (3):266-280CrossRef

150.

Aherne EA, Pak LM, Goldman DA, Gonen M, Jarnagin WR, Simpson AL, Do RK (2018) Intrahepatic cholangiocarcinoma: can imaging phenotypes predict survival and tumor genetics? Abdominal radiology (New York). https://doi.org/10.1007/s00261-018-1505-4

151.

DeLeon T, Borad MJ, Wu T, Li J, Zwart CM, Yang G, Holeman S, Silva AC (2017) Utility of CT texture for identification of FGFR2 fusion in cholangiocarcinoma: A radiogenomic pilot study. Journal of Clinical Oncology Conference 35 (15 Supplement 1)

152.

Gudbjartsson T, Thoroddsen A, Petursdottir V, Hardarson S, Magnusson J, Einarsson GV (2005) Effect of incidental detection for survival of patients with renal cell carcinoma: results of population-based study of 701 patients. Urology 66 (6):1186-1191. https://doi.org/10.1016/j.urology.2005.07.009 CrossRefPubMed

153.

Cowey CL, Rathmell WK (2009) VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Curr Oncol Rep 11 (2):94-101CrossRefPubMedPubMedCentral

154.

Zhang J, Zhang Q (2018) VHL and Hypoxia Signaling: Beyond HIF in Cancer. Biomedicines 6 (1). https://doi.org/10.3390/biomedicines6010035

155.

Karlo CA, Di Paolo PL, Chaim J, Hakimi AA, Ostrovnaya I, Russo P, Hricak H, Motzer R, Hsieh JJ, Akin O (2014) Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations. Radiology 270 (2):464-471. https://doi.org/10.1148/radiol.13130663 CrossRefPubMed

156.

Chen X, Zhou Z, Thomas K, Wang J (2016) Predicting gene mutations in renal cell carcinoma based on CT imaging features: Validation using TCGA-TCIA datasets. Medical physics 43 (6 PART2):3705

157.

da Costa WH, da Cunha IW, Fares AF, Bezerra SM, Shultz L, Clavijo DA, da Silva DV, Netto GJ, Guimaraes GC, Cassio Zequi S (2018) Prognostic impact of concomitant loss of PBRM1 and BAP1 protein expression in early stages of clear cell renal cell carcinoma. Urol Oncol 36 (5):243 e241-243 e248. https://doi.org/10.1016/j.urolonc.2018.01.002

158.

Wi YC, Moon A, Jung MJ, Kim Y, Bang SS, Jang K, Paik SS, Shin SJ (2018) Loss of Nuclear BAP1 Expression Is Associated with High WHO/ISUP Grade in Clear Cell Renal Cell Carcinoma. J Pathol Transl Med 52 (6):378-385. https://doi.org/10.4132/jptm.2018.09.21 CrossRefPubMedPubMedCentral

159.

Sohrabi S, Vikram R (2017) Correlation of CT derived textual features with mutational status of clear cell renal cell carcinoma-preliminary findings. Abdominal Radiology 42 (8):2030-2031. doi:http://dx.doi.org/10.1007/s00261-017-1192-6 CrossRef

160.

Shinagare AB, Vikram R, Jaffe C, Akin O, Kirby J, Huang E, Freymann J, Sainani NI, Sadow CA, Bathala TK, Rubin DL, Oto A, Heller MT, Surabhi VR, Katabathina V, Silverman SG (2015) Radiogenomics of clear cell renal cell carcinoma: preliminary findings of The Cancer Genome Atlas-Renal Cell Carcinoma (TCGA-RCC) Imaging Research Group. Abdominal imaging 40 (6):1684-1692. https://doi.org/10.1007/s00261-015-0386-z CrossRefPubMedPubMedCentral

161.

Winer AG, Hoetker A, Vacchio MJ, Zabor EC, Ostravnaya I, Russo P, Hsieh JJ, Akin O, Hakimi AA (2015) Radiogenomics of clear cell renal cell carcinoma: Associations between imaging, molecular alterations and pathologic features. Journal of Urology 1):e423

162.

Vikram R, Ghosh P, Tamboli P, Rao A (2014) Image texture analysis to predict bap1 mutational status in patients with clear cell renal carcinoma. Abdominal imaging 39 (3):668. doi:http://dx.doi.org/10.1007/s00261-014-0161-6 CrossRef

163.

Duddalwar V, Liang G, Siegmund K, Cen S, Varghese B, Hwang D, Desai B, Desai M, Aron M, Gill I (2018) Association of computed tomography-based radiomic features with epigenetic variation of clear cell renal cell carcinoma using dna methylation. Journal of Urology 199 (4 Supplement 1):e959

164.

Guo F, Gong H, Zhao H, Chen J, Zhang Y, Zhang L, Shi X, Zhang A, Jin H, Zhang J, He Y (2018) Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients. Scientific reports 8 (1):6076. https://doi.org/10.1038/s41598-018-24306-1 CrossRefPubMedPubMedCentral

165.

Irahara N, Baba Y, Nosho K, Shima K, Yan L, Dias-Santagata D, Iafrate AJ, Fuchs CS, Haigis KM, Ogino S (2010) NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol 19 (3):157-163. https://doi.org/10.1097/pdm.0b013e3181c93fd1 CrossRefPubMedPubMedCentral

166.

Fernández-Medarde A, Santos E (2011) Ras in Cancer and Developmental Diseases. Genes & Cancer 2 (3):344-358. https://doi.org/10.1177/1947601911411084 CrossRef

167.

Zhang J, Zheng J, Yang Y, Lu J, Gao J, Lu T, Sun J, Jiang H, Zhu Y, Zheng Y, Liang Z, Liu T (2015) Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases. Scientific reports 5:18678. https://doi.org/10.1038/srep18678 CrossRefPubMedPubMedCentral

168.

Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL (2009) American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27 (12):2091-2096. https://doi.org/10.1200/jco.2009.21.9170 CrossRefPubMed

169.

Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369 (11):1023-1034. https://doi.org/10.1056/nejmoa1305275 CrossRefPubMed

170.

Lubner MG, Stabo N, Lubner SJ, del Rio AM, Song C, Halberg RB, Pickhardt PJ (2015) CT textural analysis of hepatic metastatic colorectal cancer: pre-treatment tumor heterogeneity correlates with pathology and clinical outcomes. Abdominal imaging 40 (7):2331-2337. https://doi.org/10.1007/s00261-015-0438-4 CrossRefPubMed

171.

Yang L, Dong D, Fang M, Zhu Y, Zang Y, Liu Z, Zhang H, Ying J, Zhao X, Tian J (2018) Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer? European radiology 28 (5):2058-2067. https://doi.org/10.1007/s00330-017-5146-8 CrossRefPubMed

172.

Shin YR, Kim KA, Im S, Hwang SS, Kim KJAr (2016) Prediction of KRAS mutation in rectal cancer using MRI. 36 (9):4799-4804

173.

Hong H-S, Kim SH, Park H-J, Park M-S, Kim KW, Kim WH, Kim NK, Lee JM, Cho HJJYmj (2013) Correlations of dynamic contrast-enhanced magnetic resonance imaging with morphologic, angiogenic, and molecular prognostic factors in rectal cancer. 54 (1):123-130

174.

He J (2018) Comparison of PET conventional parameters and PET texture parameters for predicting KRAS gene mutation in colorectal cancer. Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI 59 (Supplement 1)

175.

Lovinfosse P, Koopmansch B, Lambert F, Jodogne S, Kustermans G, Hatt M, Visvikis D, Seidel L, Polus M, Albert A, Delvenne P, Hustinx R (2016) (18)F-FDG PET/CT imaging in rectal cancer: relationship with the RAS mutational status. The British journal of radiology 89 (1063):20160212. https://doi.org/10.1259/bjr.20160212 CrossRefPubMedPubMedCentral

176.

Song B, Zhang G, Lu H, Wang H, Zhu W, Pickhardt PJ, Liang ZJIjocar, surgery (2014) Volumetric texture features from higher-order images for diagnosis of colon lesions via CT colonography. 9 (6):1021-1031

177.

Chen S-W, Lin C-Y, Ho C-M, Chang Y-S, Yang S-F, Kao C-H, Chang J-GJCnm (2015) Genetic alterations in colorectal Cancer have different patterns on 18F-FDG PET/CT. 40 (8):621-626

178.

Pershad Y, Govindan S, Hara A, Borad M, Bekaii-Saab T, Wallace A, Albadawi H, Oklu RJD (2017) Using Naïve Bayesian Analysis to Determine Imaging Characteristics of KRAS Mutations in Metastatic Colon Cancer. 7 (3):50

179.

Jamaspishvili T, Berman DM, Ross AE, Scher HI, De Marzo AM, Squire JA, Lotan TL (2018) Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol 15 (4):222-234. https://doi.org/10.1038/nrurol.2018.9 CrossRefPubMedPubMedCentral

180.

McCann SM, Jiang Y, Fan X, Wang J, Antic T, Prior F, VanderWeele D, Oto A (2016) Quantitative Multiparametric MRI Features and PTEN Expression of Peripheral Zone Prostate Cancer: A Pilot Study. AJR American journal of roentgenology 206 (3):559-565. https://doi.org/10.2214/ajr.15.14967 CrossRefPubMed

181.

Vander-Weele DJ, McCann S, Fan X, Antic T, Jiang Y, Oto A (2015) Radiogenomics of prostate cancer: Association between quantitative multi-parametric MRI features and PTEN. Journal of Clinical Oncology Conference 33 (7 SUPPL. 1)

182.

Stoyanova R, Pollack A, Lynne C, Jorda M, Erho N, Lam LLC, Buerki C, Davicioni E, Ishkanian A (2015) Using radiogenomics to characterize MRI-guided prostate cancer biopsy heterogenity. Journal of Clinical Oncology Conference 33 (7 SUPPL. 1)

183.

Stoyanova R, Pollack A, Takhar M, Lynne C, Parra N, Lam LL, Alshalalfa M, Buerki C, Castillo R, Jorda M, Ashab HA, Kryvenko ON, Punnen S, Parekh DJ, Abramowitz MC, Gillies RJ, Davicioni E, Erho N, Ishkanian A (2016) Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies. Oncotarget 7 (33):53362-53376. https://doi.org/10.18632/oncotarget.10523 CrossRefPubMedPubMedCentral

184.

Shaikh FA, Kolowitz BJ, Awan O, Aerts HJ, von Reden A, Halabi S, Mohiuddin SA, Malik S, Shrestha RB, Deible C (2017) Technical challenges in the clinical application of radiomics. JCO Clinical Cancer Informatics 1:1-8CrossRefPubMed

185.

Leijenaar RT, Carvalho S, Velazquez ER, Van Elmpt WJ, Parmar C, Hoekstra OS, Hoekstra CJ, Boellaard R, Dekker AL, Gillies RJJAo (2013) Stability of FDG-PET Radiomics features: an integrated analysis of test-retest and inter-observer variability. 52 (7):1391-1397

186.

Traverso A, Wee L, Dekker A, Gillies RJIJoROBP (2018) Repeatability and reproducibility of radiomic features: a systematic review. 102 (4):1143-1158

187.

Fave X, Mackin D, Yang J, Zhang J, Fried D, Balter P, Followill D, Gomez D, Jones AK, Stingo FJMp (2015) Can radiomics features be reproducibly measured from CBCT images for patients with non‐small cell lung cancer? 42 (12):6784-6797

188.

Mackin D, Fave X, Zhang L, Fried D, Yang J, Taylor B, Rodriguez-Rivera E, Dodge C, Jones AK, Court LJIr (2015) Measuring CT scanner variability of radiomics features. 50 (11):757

189.

Shafiq‐ul‐Hassan M, Zhang GG, Latifi K, Ullah G, Hunt DC, Balagurunathan Y, Abdalah MA, Schabath MB, Goldgof DG, Mackin DJMp (2017) Intrinsic dependencies of CT radiomic features on voxel size and number of gray levels. 44 (3):1050-1062

190.

Berenguer R, Pastor-Juan MdR, Canales-Vázquez J, Castro-García M, Villas MV, Mansilla Legorburo F, Sabater SJR (2018) Radiomics of CT features may be nonreproducible and redundant: influence of CT acquisition parameters. 288 (2):407-415

191.

Lecler A, Duron L, Balvay D, Savatovsky J, Bergès O, Zmuda M, Farah E, Galatoire O, Bouchouicha A, Fournier LS (2019) Combining Multiple Magnetic Resonance Imaging Sequences Provides Independent Reproducible Radiomics Features. Scientific reports 9 (1):2068. https://doi.org/10.1038/s41598-018-37984-8 CrossRefPubMedPubMedCentral

192.

Shiri I, Rahmim A, Ghaffarian P, Geramifar P, Abdollahi H, Bitarafan-Rajabi AJEr (2017) The impact of image reconstruction settings on 18F-FDG PET radiomic features: multi-scanner phantom and patient studies. 27 (11):4498-4509

193.

Zhao B, Tan Y, Tsai WY, Qi J, Xie C, Lu L, Schwartz LH (2016) Reproducibility of radiomics for deciphering tumor phenotype with imaging. Scientific reports 6:23428. https://doi.org/10.1038/srep23428 CrossRefPubMedPubMedCentral

194.

van Velden FH, Kramer GM, Frings V, Nissen IA, Mulder ER, de Langen AJ, Hoekstra OS, Smit EF, Boellaard RJMi, biology (2016) Repeatability of radiomic features in non-small-cell lung cancer [18 F] FDG-PET/CT studies: impact of reconstruction and delineation. 18 (5):788-795

195.

Parmar C, Velazquez ER, Leijenaar R, Jermoumi M, Carvalho S, Mak RH, Mitra S, Shankar BU, Kikinis R, Haibe-Kains BJPo (2014) Robust radiomics feature quantification using semiautomatic volumetric segmentation. 9 (7):e102107

196.

He L, Huang Y, Ma Z, Liang C, Liang C, Liu Z (2016) Effects of contrast-enhancement, reconstruction slice thickness and convolution kernel on the diagnostic performance of radiomics signature in solitary pulmonary nodule. Scientific reports 6:34921. https://doi.org/10.1038/srep34921. https://www.nature.com/articles/srep34921#supplementary-information

197.

Perrin T, Midya A, Yamashita R, Chakraborty J, Saidon T, Jarnagin WR, Gonen M, Simpson AL, Do RKJAR (2018) Short-term reproducibility of radiomic features in liver parenchyma and liver malignancies on contrast-enhanced CT imaging. 43 (12):3271-3278

198.

Khalvati F, Zhang Y, Baig S, Lobo-Mueller EM, Karanicolas P, Gallinger S, Haider MA (2019) Prognostic Value of CT Radiomic Features in Resectable Pancreatic Ductal Adenocarcinoma. Scientific reports 9 (1):5449. https://doi.org/10.1038/s41598-019-41728-7 CrossRefPubMedPubMedCentral

199.

Altazi BA, Zhang GG, Fernandez DC, Montejo ME, Hunt D, Werner J, Biagioli MC, Moros EGJJoacmp (2017) Reproducibility of F18‐FDG PET radiomic features for different cervical tumor segmentation methods, gray‐level discretization, and reconstruction algorithms. 18 (6):32-48

200.

Coroller TP, Agrawal V, Narayan V, Hou Y, Grossmann P, Lee SW, Mak RH, Aerts HJJR, Oncology (2016) Radiomic phenotype features predict pathological response in non-small cell lung cancer. 119 (3):480-486

201.

Fiset S, Welch ML, Weiss J, Pintilie M, Conway JL, Milosevic M, Fyles A, Traverso A, Jaffray D, Metser UJR, Oncology (2019) Repeatability and reproducibility of MRI-based radiomic features in cervical cancer. 135:107-114

202.

Qiu Q, Duan J, Duan Z, Meng X, Ma C, Zhu J, Lu J, Liu T, Yin YJQIiM, Surgery (2019) Reproducibility and non-redundancy of radiomic features extracted from arterial phase CT scans in hepatocellular carcinoma patients: impact of tumor segmentation variability.

203.

Zhang J, Qiu Q, Duan J, Gong G, Jiang Q, Sun G, Yin YJTCR (2019) Variability of radiomic features extracted from multi-b-value diffusion-weighted images in hepatocellular carcinoma. 8 (1):130-140

204.

Buckler AJ, Mozley PD, Schwartz L, Petrick N, McNitt-Gray M, Fenimore C, O’Donnell K, Hayes W, Kim HJ, Clarke LJAr (2010) Volumetric CT in lung cancer: an example for the qualification of imaging as a biomarker. 17 (1):107-115

205.

Wiki FQ, Body QF-PW The Radiological Society of North America (RSNA) Quantitative Imaging Biomarker Alliance (QIBA) FDG-PET Technical Committee: Proffered Protocol for Quantifying the Standard Uptake (SUV) in Patients with Cancer.

206.

Hussain Z, Gimenez F, Yi D, Rubin D Differential data augmentation techniques for medical imaging classification tasks. In: AMIA Annual Symposium Proceedings, 2017. American Medical Informatics Association, p 979

207.

Banerjee S, Mitra S, Shankar BU, Hayashi Y (2016) A Novel GBM Saliency Detection Model Using Multi-Channel MRI. PloS one 11 (1):e0146388. https://doi.org/10.1371/journal.pone.0146388 CrossRefPubMedPubMedCentral

208.

De Fauw J, Ledsam JR, Romera-Paredes B, Nikolov S, Tomasev N, Blackwell S, Askham H, Glorot X, O’Donoghue B, Visentin D, van den Driessche G, Lakshminarayanan B, Meyer C, Mackinder F, Bouton S, Ayoub K, Chopra R, King D, Karthikesalingam A, Hughes CO, Raine R, Hughes J, Sim DA, Egan C, Tufail A, Montgomery H, Hassabis D, Rees G, Back T, Khaw PT, Suleyman M, Cornebise J, Keane PA, Ronneberger O (2018) Clinically applicable deep learning for diagnosis and referral in retinal disease. Nature Medicine 24 (9):1342-1350. https://doi.org/10.1038/s41591-018-0107-6 CrossRefPubMed

209.

Velazquez ER, Parmar C, Jermoumi M, Mak RH, van Baardwijk A, Fennessy FM, Lewis JH, De Ruysscher D, Kikinis R, Lambin P, Aerts HJ (2013) Volumetric CT-based segmentation of NSCLC using 3D-Slicer. Scientific reports 3:3529. https://doi.org/10.1038/srep03529 CrossRefPubMedPubMedCentral

210.

Joskowicz L, Cohen D, Caplan N, Sosna J (2018) Inter-observer variability of manual contour delineation of structures in CT. European radiology. https://doi.org/10.1007/s00330-018-5695-5

211.

Binder ZA, Thorne AH, Bakas S, Wileyto EP, Bilello M, Akbari H, Rathore S, Ha SM, Zhang L, Ferguson CJ, Dahiya S, Bi WL, Reardon DA, Idbaih A, Felsberg J, Hentschel B, Weller M, Bagley SJ, Morrissette JJD, Nasrallah MP, Ma J, Zanca C, Scott AM, Orellana L, Davatzikos C, Furnari FB, O’Rourke DM (2018) Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development. Cancer cell 34 (1):163-177.e167. https://doi.org/10.1016/j.ccell.2018.06.006 CrossRefPubMedPubMedCentral

212.

Beig N, Patel J, Prasanna P, Hill V, Gupta A, Correa R, Bera K, Singh S, Partovi S, Varadan V, Ahluwalia M, Madabhushi A, Tiwari P (2018) Radiogenomic analysis of hypoxia pathway is predictive of overall survival in Glioblastoma. Scientific reports 8 (1):7. https://doi.org/10.1038/s41598-017-18310-0 CrossRefPubMedPubMedCentral

213.

Colen R, Foster I, Gatenby R, Giger ME, Gillies R, Gutman D, Heller M, Jain R, Madabhushi A, Madhavan S, Napel S, Rao A, Saltz J, Tatum J, Verhaak R, Whitman G (2014) NCI Workshop Report: Clinical and Computational Requirements for Correlating Imaging Phenotypes with Genomics Signatures. Translational oncology 7 (5):556-569. https://doi.org/10.1016/j.tranon.2014.07.007 CrossRefPubMedPubMedCentral

214.

Colen R, Hatami M, Kotrotsou A, Chaddad A, Bakhtiari A, Luedi M, Zinn PO (2015) Radiomic subclassification of glioblastoma. Neuro-oncology 5):v155. http://dx.doi.org/10.1093/neuonc/nov225.11 CrossRef

2024 ASCO Annual Meeting

Springer Medicine

Radiogenomics: bridging imaging and genomics

Abstract

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2019

Deep transfer learning-based prostate cancer classification using 3 Tesla multi-parametric MRI

Teardrop sign

Radiomics and radiogenomics of prostate cancer

Image quality and diagnostic accuracy of complex-averaged high b value images in diffusion-weighted MRI of prostate cancer

Tissue sampling in the era of precision medicine: comparison of percutaneous biopsies performed for clinical trials or tumor genomics versus routine clinical care

Are we at a crossroads or a plateau? Radiomics and machine learning in abdominal oncology imaging

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials